For the quarter ended March 2025, APA (APA) reported revenue of $2.61 billion, up 37.3% over the same period last year. EPS came in at $1.06, compared to $0.78 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $2.21 billion, representing a surprise of +18.00%. The company delivered an EPS surprise of +27.71%, with the consensus EPS estimate being $0.83. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

For the quarter ended March 2025, FS KKR Capital (FSK) reported revenue of $400 million, down 7.8% over the same period last year. EPS came in at $0.65, compared to $0.73 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $396.62 million, representing a surprise of +0.85%. The company delivered an EPS surprise of +1.56%, with the consensus EPS estimate being $0.64. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Core Insights - Coherent reported a revenue of $1.5 billion for the quarter ended March 2025, reflecting a year-over-year increase of 23.9% and exceeding the Zacks Consensus Estimate of $1.44 billion by 3.97% [1] - The company's EPS for the quarter was $0.91, up from $0.53 in the same quarter last year, surpassing the consensus EPS estimate of $0.86 by 5.81% [1] Revenue Performance - Revenue from Materials was $236.70 million, slightly above the estimated $236.16 million, but down 1% year-over-year [4] - Networking revenues reached $897.30 million, exceeding the average estimate of $842.47 million, marking a significant year-over-year increase of 45% [4] - Lasers generated $363.90 million in revenue, slightly above the estimated $359.34 million, with a year-over-year growth of 3.7% [4] - Instrumentation revenue was $95.62 million, below the average estimate of $100.73 million, representing a decline of 2.7% year-over-year [4] - Communications revenue was $896.99 million, surpassing the estimate of $835.13 million, with a year-over-year increase of 45.7% [4] - Industrial revenue was $439.55 million, slightly above the estimated $429.76 million, reflecting a 4.4% year-over-year increase [4] - Electronics revenue was $65.72 million, below the average estimate of $72.64 million, indicating a year-over-year decline of 10.7% [4] Stock Performance - Coherent's shares have returned +35.8% over the past month, significantly outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Supplemental Financial Tables Q1 2025 May 2025 ©2025 Carvana, LLC Supplemental Financial Tables Over the last several years we reported three non-GAAP financial metrics to clearly demonstrate and highlight the most meaningful drivers within our business: Non-GAAP Gross Profit, Non-GAAP SG&A Expense, and Adjusted EBITDA. The Non-GAAP metrics presented in these tables do not represent and should not be considered an alternative to gross profit, SG&A expense, or net income (loss), as determined by U.S. GAAP. N ...

View all Key Company Metrics for GCM Grosvenor here>>> While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price perfor ...

Edgewell Personal Care (EPC) reported $580.7 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.1%. EPS of $0.87 for the same period compares to $0.88 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $590.67 million, representing a surprise of -1.69%. The company delivered an EPS surprise of -3.33%, with the consensus EPS estimate being $0.90.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...

Core Insights - MarketAxess reported revenue of $208.58 million for the quarter ended March 2025, a decrease of 0.8% year-over-year, with EPS at $1.87 compared to $1.92 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $210.63 million, resulting in a surprise of -0.97%, while the EPS exceeded the consensus estimate of $1.82 by +2.75% [1] Financial Performance Metrics - Average Variable Transaction Fee Per Million - Credit was $139, below the five-analyst average estimate of $143.75 [4] - Average Daily Volume - Total reached $42.91 billion, surpassing the five-analyst average estimate of $40.74 billion [4] - Average Daily Volume - Total credit trading was $15.92 billion, slightly below the estimated $16.04 billion [4] - Average Daily Volume - Total rates trading was $26.98 billion, exceeding the five-analyst average estimate of $24.70 billion [4] - Revenues from Information services were $12.90 million, slightly below the estimate of $12.99 million, but represented an increase of +8.6% year-over-year [4] - Revenues from Commissions totaled $181.34 million, compared to the average estimate of $185.39 million, reflecting a -1.9% change year-over-year [4] - Revenues from Technology services were $3.24 million, slightly below the estimate of $3.29 million, with a year-over-year increase of +14.4% [4] - Revenues from Post-trade services were $11.09 million, compared to the average estimate of $11.14 million, representing a +3.3% change year-over-year [4] - Total commission revenue from variable transaction fees - Rates was $6.92 million, exceeding the four-analyst average estimate of $6.71 million, with a year-over-year change of +33.9% [4] - Total commission revenue from variable transaction fees - Credit was $135.84 million, below the estimated $139.51 million, reflecting a -4% change year-over-year [4] - Total commission revenue from fixed distribution fees was $33.35 million, slightly above the four-analyst average estimate of $32.36 million, with no change year-over-year [4] Stock Performance - MarketAxess shares returned +11% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Q1 2025 results 07 May 2025 Financial Data and Use of Projections and Illustrative Presentations Disclaimer This presentation has been prepared for use by Forge Global Holdings, Inc. ("Forge") for informational purposes only and may not be reproduced or redistributed, in whole or in part, without the prior written consent of Forge. Forge does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. The information in this presentation and ...

Core Insights - IQVIA Holdings reported $3.83 billion in revenue for Q1 2025, a year-over-year increase of 2.5% and an EPS of $2.70, up from $2.54 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $3.77 billion by 1.55%, and the EPS also surpassed the consensus estimate of $2.63 by 2.66% [1] Financial Performance Metrics - The backlog stood at $31.5 billion, slightly above the average estimate of $31.43 billion from two analysts [4] - Revenue from Technology & Analytics Solutions was $1.55 billion, exceeding the estimated $1.52 billion, reflecting a 6.4% increase year-over-year [4] - Revenue from Research & Development Solutions reached $2.10 billion, slightly above the $2.08 billion estimate, with a year-over-year change of 0.3% [4] - Revenue from Contract Sales & Medical Solutions was $181 million, below the estimated $183.42 million, showing a year-over-year decline of 4.2% [4] - Segment profit for Technology & Analytics Solutions was $360 million, compared to the estimated $365.56 million [4] - Segment profit for Contract Sales & Medical Solutions was $11 million, below the estimated $15.65 million [4] - Segment profit for Research & Development Solutions was $460 million, compared to the estimated $471.69 million [4] Stock Performance - IQVIA shares have returned -0.5% over the past month, while the Zacks S&P 500 composite increased by 11.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Myriad Genetics reported $195.9 million in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 3.1% and an EPS of -$0.03 compared to -$0.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $199.96 million by 2.03%, while the EPS exceeded the consensus estimate of -$0.05 by 40% [1] Revenue Performance by Product - Prenatal revenue reached $49.30 million, surpassing the estimated $44.69 million, marking a year-over-year increase of 59.6% [4] - Hereditary Cancer revenue was $86.30 million, below the average estimate of $92.46 million, representing a year-over-year decline of 2% [4] - Pharmacogenomics revenue totaled $31 million, slightly below the estimated $32.46 million, with a year-over-year decrease of 20.3% [4] - Tumor Profiling revenue was $29.30 million, compared to the average estimate of $30.66 million, indicating a year-over-year decline of 5.2% [4] Stock Performance - Myriad's shares have returned -4.6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]